Update on the treatment of metastatic clear cell and non-clear cell renal cell carcinoma

Biomarker Research

Shenhong Wu²  Kevin Y Xu¹ 

[1]Department of Medical Education, Icahn School of Medicine at Mount Sinai, New York, NY, USA

[2]Northport VA Medical Center, Northport, NY, USA

关键词: Tyrosine kinase inhibitor;    PD-1;    Non-clear cell;    Clear cell;    Renal cell carcinoma;   

Others  :  1135621
DOI  :  10.1186/s40364-015-0030-7

 received in 2014-12-23, accepted in 2015-02-02,  发布年份 2015

【 摘 要 】

The advent of new knowledge surrounding the molecular pathology of renal-cell carcinoma (RCC) has culminated in a number of emerging targeted therapies. In just the last year, several new studies have been able to translate our understanding of tumor biology into significantly improved outcomes in patients with advanced RCC. The objective of this review is to describe new developments in targeted treatments and immunotherapies for patients with both clear-cell and non-clear cell metastatic RCC following the 2014 American Society of Clinical Oncology (ASCO) annual conference. We will discuss new applications of anti-VGF agents and PD-1 inhibitors in order to shed light on emerging avenues of RCC treatment that show considerable promise.

【 授权许可】

   
2015 Xu and Wu; licensee BioMed Central.

【 参考文献 】

• [1]Siegel R, Naishadham D, Jemal A: Cancer statistics, 2012. CA Cancer J Clin 2012, 62:10-29.
• [2]Cowey CL, Rathmell WK: VHL gene mutations in renal cell carcinoma: role as a biomarker of disease outcome and drug efficacy. Curr Oncol Rep 2009, 11:94-101.
• [3]Logan JE, Rampersaud EN, Sonn GA, Chamie K, Belldegrun AS, Pantuck AJ, et al.: Systemic therapy for metastatic renal cell carcinoma: a review and update. Rev Urol 2012, 14:65-78.
• [4]Thompson Coon J, Hoyle M, Green C, Liu Z, Welch K, Moxham T, et al.: Bevacizumab, sorafenib tosylate, sunitinib and temsirolimus for renal cell carcinoma: a systematic review and economic evaluation. Health Technol Assess 2010, 14:1-184.
• [5]Escudier B, Pluzanska A, Koralewski P, Ravaud A, Bracarda S, Szczylik C, et al.: Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet 2007, 370:2103-11.
• [6]Sternberg CN, Davis ID, Mardiak J, Szczylik C, Lee E, Wagstaff J, et al.: Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. J Clin Oncol 2010, 28:1061-8.
• [7]Escudier B, Eisen T, Stadler WM, Szczylik C, Oudard S, Siebels M, et al.: Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007, 356:125-34.
• [8]Rini BI, Escudier B, Tomczak P, Kaprin A, Szczylik C, Hutson TE, et al.: Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial. Lancet 2011, 378:1931-9.
• [9]Hudes G, Carducci M, Tomczak P, Dutcher J, Figlin R, Kapoor A, et al.: Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 2007, 356:2271-81.
• [10]Kalra S, Verma J, Atkinson BJ, Matin SF, Wood CG, Karam JA, et al.: Outcomes of patients with metastatic renal cell carcinoma and bone metastases in the targeted-therapy era. In Book Outcomes of patients with metastatic renal cell carcinoma and bone metastases in the targeted-therapy era (Editor ed.^eds.). 2014 Genitourinary Cancers Symposium, City; 2014.
• [11]Ribas A, Hodi FS, Kefford R, Hamid O, Daud A, Wolchok JD, et al.: Immunomodulatory activity of nivolumab in previously treated and untreated metastatic renal cell carcinoma (mRCC): Biomarker-based results from a randomized clinical trial. In Book Immunomodulatory activity of nivolumab in previously treated and untreated metastatic renal cell carcinoma (mRCC): Biomarker-based results from a randomized clinical trial. (Editor ed.^eds.). ASCO Annual Meeting, City; 2014.
• [12]Sznol M, Kluger HM, Callahan MK, Postow MA, Gordon RA, Segal NH, et al.: Survival, response duration, and activity by BRAF mutation status of nivolumab (NIVO, anti-PD-1, BMS-936558, ONO-4538) and ipilimumab concurrent therapy in advanced melanoma. In Book Survival, response duration, and activity by BRAF mutation status of nivolumab (NIVO, anti-PD-1, BMS-936558, ONO-4538) and ipilimumab concurrent therapy in advanced melanoma (Editor ed.^eds.). ASCO Annual Meeting, City; 2014.
• [13]Hammers HJ, Plimack ER, Infante JR, Ernstoff MS, Rini BI, McDermott D, et al.: Phase I study of nivolumab in combination with ipilimumab in metastatic renal cell carcinoma (mRCC). In Book Phase I study of nivolumab in combination with ipilimumab in metastatic renal cell carcinoma (mRCC). (Editor ed.^eds.). American Society of Clinical Oncology (ASCO), City; 2014.
• [14]Gunturi A, McDermott DF: Potential of new therapies like anti-PD1 in kidney cancer. Curr Treat Options Oncol 2014, 15:137-46.
• [15]Motzer RJ, Rini BI, McDermott DF, Redman BG, Kuzel T, Harrison MR, et al.: Nivolumab for metastatic renal cell carcinoma (mRCC): Results of a randomized, dose-ranging phase trial. In Book Nivolumab for metastatic renal cell carcinoma (mRCC): Results of a randomized, dose-ranging phase trial (Editor ed.^eds.). ASCO Annual Meeting, City; 2014.
• [16]Choueiri TK, Fishman MN, Escudier B, Kim JJ, Kluger HM, Stadler WM, et al.: Immunomodulatory activity of nivolumab in previously treated and untreated metastatic renal cell carcinoma (mRCC): Biomarker-based results from a randomized clinical trial. In Book Immunomodulatory activity of nivolumab in previously treated and untreated metastatic renal cell carcinoma (mRCC): Biomarker-based results from a randomized clinical trial (Editor ed.^eds.). ASCO Annual Meeting, City; 2014.
• [17]Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Rixe O, et al.: Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 2007, 356:115-24.
• [18]Motzer RJ, Escudier B, Oudard S, Hutson TE, Porta C, Bracarda S, et al.: Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet 2008, 372:449-56.
• [19]Tannir NM, Jonasch E, Altinmakas E, Ng CS, Qiao W, Tamboli P, et al.: Everolimus versus sunitinib prospective evaluation in metastatic non-clear cell renal cell carcinoma (The ESPN Trial): a multicenter randomized phase 2 trial. In Book Everolimus versus sunitinib prospective evaluation in metastatic non-clear cell renal cell carcinoma (The ESPN Trial): A multicenter randomized phase 2 trial (Editor ed.^eds.). ASCO Annual Meeting, City; 2014.
• [20]Hudes GR: Targeting mTOR in renal cell carcinoma. Cancer 2009, 115:2313-20.